Plus Therapeutics Inc Stock Price, News & Analysis

Plus Therapeutics (PSTV) has partnered with RadioMedix for the commercial production of Rhenium-186 NanoLiposome (186RNL), a targeted radiotherapeutic for recurrent glioblastoma. This strategic alliance aims to ensure cGMP compliance, facilitating clinical studies slated for mid-2022. 186RNL is designed to effectively deliver radiation to central nervous system tumors. Plus Therapeutics is currently conducting a Phase 1 clinical trial for recurrent GBM, leveraging NIH support.

Plus Therapeutics has reported promising data from its ReSPECT™ Phase 1 trial for Rhenium-186 NanoLiposome (¹⁸⁶RNL) in treating recurrent glioblastoma. The investigational drug demonstrated good tolerance at high radiation doses, outperforming standard therapies. Key findings include a mean dose of 392 Gy delivered safely, with no serious adverse events noted. The company plans to expand research into pediatric brain tumors, starting a Phase 1 study by mid-2022. The overall response rate will be a primary endpoint in the upcoming trials.

Plus Therapeutics (PSTV) recently presented promising preclinical data supporting its FDA IND application for Rhenium-186 Nanoliposome (186RNL) targeted radiotherapy aimed at treating leptomeningeal metastases (LM). The data, showcased at the Society for Neuro-Oncology's conference, indicated minimal toxicity and significant efficacy in animal models. Plans for a Phase 1 dose escalation clinical trial with patient accrual expected in Q4 2021 were also outlined. The trial will evaluate the treatment's safety and efficacy in patients previously treated for breast or non-small cell lung cancer with LM.

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced it will present data on Rhenium-186 NanoLiposome from its Phase 1 ReSPECT™ trial for recurrent glioblastoma at the American Association of Neurological Surgeons 2021 Annual Scientific Meeting, held virtually from August 21-25, 2021. The presentation titled "A two-part, Phase 1 study of Rhenium-186 NanoLiposome" will be made available on-demand beginning August 21. Lead presenter Michael G. DeCuypere, MD, PhD, will provide insights on the study's findings, which aim to enhance treatment for rare cancers.

AUSTIN, Texas, Aug. 11, 2021 – Plus Therapeutics (Nasdaq: PSTV) announced data presentation at the Third Annual Conference on Brain Metastases by the Society for Neuro-Oncology. The studies evaluate Rhenium-186 Nanoliposome (186RNL) for leptomeningeal metastases treatment. Andrew J. Brenner, M.D., will present findings from the ongoing ReSPECT-GBM Phase 1 trial and a preclinical study showing that 186RNL is well tolerated and improves survival in animal models. The conference runs from August 19-20, 2021, with data available to attendees.

Plus Therapeutics (PSTV) announced that CEO Marc H. Hedrick M.D. will provide a company overview at the Canaccord Genuity 41st Annual Growth Conference on August 12, 2021, at 4:30 p.m. ET. The presentation will focus on Plus Therapeutics' innovative radiotherapeutics targeting rare cancers, utilizing a unique nanotechnology platform. Investors wishing to schedule meetings can contact the conference coordinator. A webcast will be available in the Investor Relations section of the Plus Therapeutics website.

Plus Therapeutics, Inc. (PSTV) has entered a ten-year exclusivity agreement with ABX Advanced Biochemical Compounds GmbH for the supply of a key component in the manufacturing of Rhenium-186 NanoLiposome (186RNL), their lead radiotherapeutic. This partnership will ensure a high purity precursor produced under cGMP, meeting FDA standards. The agreement not only strengthens Plus Therapeutics’ supply chain but also secures long-term market protection around their RNL portfolio, which is key in treating recurrent glioblastoma and other rare cancers.

Plus Therapeutics, Inc. (Nasdaq: PSTV) announced its financial results for Q2 2021, reporting a net loss of $2.8 million, or $(0.25) per share. The company's cash balance increased to $17.2 million, up from $8.3 million at year-end 2020. Highlights include ongoing clinical trials for the Rhenium-186 NanoLiposome (186RNL) targeting recurrent glioblastoma, with 22 patients treated and an eighth cohort underway. The company plans to submit IND applications for Leptomeningeal Metastases and Pediatric Brain Cancer trials by year-end 2021. A conference call will discuss these results at 5:00 PM ET today.

Plus Therapeutics, Inc. (PSTV) announced the successful treatment of the first patient in the eighth cohort of their Phase 1 ReSPECT™-GBM clinical trial for recurrent glioblastoma. This cohort features a 40% increase in treatment volume and radioactivity compared to previous cohorts. To date, 22 patients have been treated across eight cohorts with no dose-limiting toxicities reported. The trial is progressing as scheduled, and an update is expected in Q4 2021.